(Circulation. 1995;91:1368-1374.)
© 1995 American Heart Association, Inc.
Articles |
From Queen's University (J.O.P.), Kingston, Ontario, Canada, and 3M Pharmaceuticals, St Paul, Minn.
Correspondence to John O. Parker, MD, Cardiovascular LabKidd 3, Kingston General Hospital, 76 Stuart St, Kingston, Ontario, Canada K7L 2V7.
Background The objectives of this study were to assess the antianginal and anti-ischemic effects of three dose levels of transdermal nitroglycerin patches applied for 12 hours daily for 30 days. The study also assessed the development of tolerance and rebound. Intermittent transdermal nitroglycerin therapy with a patch-free period of 10 to 12 hours each day has documented clinical benefits during the period of patch application, but studies have failed to clearly document prolonged exercise duration for the entire period of patch application. This study was designed to evaluate the efficacy and duration of action of a range of doses of nitroglycerin. The study also permitted the assessment of the maintenance of initial effects, the development of tolerance, and the presence of rebound.
Methods and Results This study was a multicenter, randomized, double-blind, placebo-controlled parallel design trial with treadmill exercise tests at days 0, 1, 7, 15, and 30. Tests were carried out up to 12 hours after patch application. There was a statistically significant treatment effect with increases in treadmill walking time to moderate angina in each nitroglycerin patch group compared with placebo at various time points up to 12 hours throughout the 30-day study period. Secondary efficacy parameters, including the consistent increase in time to 1-mm ST-segment depression, supported the primary efficacy results. There was no evidence of tolerance or rebound.
Conclusions Intermittent transdermal nitroglycerin therapy increases exercise duration and maintains anti-ischemic effects for 12 hours after patch application, throughout 30 days of therapy, without significant evidence of nitrate tolerance or rebound phenomena.
Key Words: angina nitroglycerin exercise
This article has been cited by other articles:
![]() |
T. Gori and J. D. Parker Nitrate-Induced Toxicity and Preconditioning: A Rationale for Reconsidering the Use of These Drugs J. Am. Coll. Cardiol., July 22, 2008; 52(4): 251 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Chaitman, S. L. Skettino, J. O. Parker, P. Hanley, J. Meluzin, J. Kuch, C. J. Pepine, W. Wang, J. J. Nelson, D. A. Hebert, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1375 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Chaitman Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S47 - S64. [Abstract] [PDF] |
||||
![]() |
J. George, I. Kitzis, D. Zandorf, M. Golovner, I. Shapira, S. Laniado, and A. Roth Safety of Nitrate Withdrawal in Angina-Free and Hemodynamically Stable Patients With Coronary Artery Disease Chest, November 1, 2003; 124(5): 1652 - 1657. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Zvara Treatment of Perioperative Myocardial Ischemia Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 2001; 5(2): 166 - 183. [Abstract] [PDF] |
||||
![]() |
M. Eccles, N. Rousseau, P. Adams, and L. Thomas Evidence-based guideline for the primary care management of stable angina Fam. Pract., April 1, 2001; 18(2): 217 - 222. [Full Text] [PDF] |
||||
![]() |
E. R. Azevedo, A. M. Schofield, S. Kelly, and J. D. Parker Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine J. Am. Coll. Cardiol., February 1, 2001; 37(2): 505 - 509. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Zwinderman, T. J. Cleophas, H. van der Sluijs, M. G. Niemeyer, B. P. Buunk, E. E. van der Wall, T. J. Cleophas, and Dutch Mononitrate Quality of Life Study Group Comparison of 50-mg and 100-mg Sustained-Release Isosorbide Mononitrate in the Treatment of Stable Angina Pectoris: Effects on Quality-of-Life Indices Angiology, December 1, 1999; 50(12): 963 - 969. [Abstract] [PDF] |
||||
![]() |
P. R. A. Caramori, A. G. Adelman, E. R. Azevedo, G. E. Newton, A. B. Parker, and J. D. Parker Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1969 - 1974. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zanzinger, J. Czachurski, and H. Seller Impaired Modulation of Sympathetic Excitability by Nitric Oxide After Long-term Administration of Organic Nitrates in Pigs Circulation, June 16, 1998; 97(23): 2352 - 2358. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Parker and J. O. Parker Nitrate Therapy for Stable Angina Pectoris N. Engl. J. Med., February 19, 1998; 338(8): 520 - 531. [Full Text] [PDF] |
||||
![]() |
INTERMITTENT NITROGLYCERIN PATCHES EFFECTIVE WITHOUT REBOUND Journal Watch (General), March 14, 1995; 1995(314): 3 - 3. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |